Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.
Executive Summary
While other companies have been hit with heftier fines for falsely marketing their drugs, Purdue Pharma's $700.6 million agreement with the Department of Justice over OxyContin promotions has had a profound impact on the management of the company, with guilty pleas from two of the firm's top executives
You may also be interested in...
Purdue Pharma: From Blockbuster Success To Bankrupt Villain
Purdue's rise and fall through opioids will likely end in bankruptcy, raising new questions around ongoing lawsuits and shining a light on the toll the opioid liability will leave on the industry.
Opioid Litigation: Drug Mfrs. Lose Bid To Limit Data Disclosure; First Trials Set For March
US court orders firms to release information on all opioid products ever classified as Schedule II from one year prior to launch date; government, manufacturers oppose public disclosure of DEA distribution data.
Opioid Litigation: US DOJ Intensifies Pressure On Sponsors With New Task Force
Task force will target unlawful marketing by opioid manufacturers, assist state lawsuits, and seek compensation for costs of opioid crisis.